Effect of once-weekly teriparatide for bone metabolism in praimary osteoprosis patients.

Effect of once-weekly teriparatide for bone metabolism in praimary osteoprosis patients. - Effect of once-weekly teriparatide for bone metabolism.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032090

Enrollment

Registered

2018-06-28

Start date

2013-07-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoprosis

Interventions

Treatment with once-weekly teriparatide was investigated change of BMD and change of serum sclerostine concentration during 18 months.Bone metabolism markers are measured before treatment, 1, 3, 6, 1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Osteoporosis was diagnosed by BMD in less than 70% of the young adult mean (YAM) in the Japanese population or the presence of fragility fractures and BMD in less than 80% of YAM.

Exclusion criteria

Exclusion criteria: Patients who are already have treated for osteporosis. Rheumatoid arthritis, dialysis patients and high vaule of PTH patients.

Design outcomes

Primary

Measure	Time frame
Changes in the serum sclerostin concentration during the 18-month treatment.	—

Secondary

Measure	Time frame
Relationship between change of BMD and sclerostin during the 18-month treatment.	—

Countries

Japan

Contacts

Public ContactTerumasa Ikeda

Kindai University Hospital Orthopaedic surgery

tikeda@med.kindai.ac.jp072-366-0221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026